Mendelian randomization: A novel approach for the prediction of adverse drug events and drug repurposing opportunities

International Journal of Epidemiology

Volumn 46, Issue 6, 2017, Pages 2078-2089

  Walker, Venexia M ^a,b   Smith, George Davey ^a,b   Davies, Neil M ^a,b   Martin, Richard M ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adverse drug events; Drug repurposing; Mendelian randomization; Pharmacovigilance

Indexed keywords

BIOLOGICAL MARKER; DRUG;

ANALYTICAL METHOD; DISEASE TREATMENT; DRUG; HEALTH CARE; OBSERVATIONAL METHOD; PREDICTION; RESEARCH METHOD; TRIANGULATION;

ADVERSE DRUG REACTION; ARTICLE; DISEASE COURSE; DRUG APPROVAL; DRUG EFFECT; DRUG INDICATION; DRUG REPOSITIONING; DRUG SURVEILLANCE PROGRAM; GENETIC VARIABILITY; GENOMICS; HUMAN; MENDELIAN RANDOMIZATION ANALYSIS; PLEIOTROPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

DRUG REPOSITIONING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; PHARMACOVIGILANCE; PROGNOSIS;

EID: 85039556034     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyx207     Document Type: Article

References (74)

1. Corbett A, Pickett J, Burns A et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012;11:833-46
2. NICE Critical Knowledge Summaries. Adverse Drug Reactions. http://cks.nice.org.uk/adverse-drug-reactions#!topicsummary (23 June 2016, date last accessed)
3. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. PharmacoepidemiolDrug Saf 2003;12:17-29
4. Uppsala Monitoring Centre. Vigibase. http://www.who-umc.org/DynPage.aspx?i=98082&mn1=7347&mn2=7252&mn3=7322&mn4=7326 (23 June 2016, date last accessed)
5. Medicines and Healthcare Products Regulatory Agency. Yellow Card Scheme. https://yellowcard.mhra.gov.uk/(23 June 2016, date last accessed)
6. U.S. Food and Drug Administration. Adverse Event Reporting System. http://www.fda.gov/Drugs/GuidanceComplianceRegu latoryInformation/Surveillance/AdverseDrugEffects/default.htm (23 June 2016, date last accessed)
7. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83
8. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22
9. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42
10. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23:R89-98
11. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int J Epidemiol 2016;45:1866-86
12. HolmesMV, Ala-KorpelaM, Davey Smith G.Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 2017, Jun 1. doi: 10.1038/nrcardio.2017.78
13. Tuffs A. Bayer faces potential fine over cholesterol lowering drug. BMJ 2001;323:415
14. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-07
15. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis.N Engl J Med 2002;346:539-40
16. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388:2532-61
17. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
18. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10:543-59
19. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoAreductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001; 49:281-87
20. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003;24:225-48
21. Laufs U, Wassmann S, Hilgers S, Ribaudo N, BöhmM, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001;88:1306-07
22. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-79
23. Swerdlow DI, Preiss D, Kuchenbaecker KB et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61
24. Kathiresan S, Melander O, Guiducci C et al. Six new loci associated with blood low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-97
25. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
26. Lotta LA, Sharp SJ, Burgess S et al. Association between lowdensity lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 2016;316:1383-91
27. Ference BA, Robinson JG, Brook RD et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144-53
28. Medicines and Health Care Products Regulatory Agency. Drug Safety Update-Statins: Risk of Hyperglycaemia and Diabetes. 2012 https://www.gov.uk/drug-safety-update/statins-risk-ofhyperglycaemia-and-diabetes (23 June 2016, date last accessed)
29. U.S. Food and Drug Administration. Consumer Health Information-FDA Expands Advice on Statin Risk Siver Spring, MD: FDA, 2014
30. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45: 1274-83
31. Kaitin K. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010;87:356-61
32. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003;2: 695-702
33. Yin P, Anttila V, Siewert KM, Palotie A, Davey Smith G, Voight BF. Serum calcium and risk of migraine: a Mendelian randomization study. Hum Mol Genet 2017;26:820-28
34. Finan C, Gaulton A, Kruger FA et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med 2017, Mar 29. doi: 10.1126/scitr anslmed.aag1166
35. Stitziel NO, Kathiresan S. Leveraging human genetics to guide drug target discovery. Trends Cardiovasc Med 2017;27:352-59
36. Nelson MR, Johnson T, Warren L et al. The genetics of drug efficacy: opportunities and challenges. Nat Rev Genet 2016;17: 197-206
37. Sanseau P, Agarwal P, Barnes MR et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol 2012; 30:317-20
38. Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM. Opportunities for drug repositioning from phenome-wide association studies. Nat Biotechnol 2015;33:342-45
39. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11:241-46
40. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012;52:21-35
41. Millard LAC, Davies NM, Timpson NJ, Tilling K, Flach PA, Davey Smith G. MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization. Sci Rep 2015;5:16645
42. The Interleukin 1 Genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2015;3:243-53
43. Matteini AM, Li J, Lange EM et al. Novel gene variants predict s65(1):1erum levels of the cytokines IL-18 and IL-1ra in older adults. Cytokine 2014;65:10-16
44. Novartis. Novartis Phase III Study Shows ACZ885 (Canakinumab) Reduces Cardiovascular Risk in People Who Survived a Heart Attack. https://www.novartis.com/news/media-releases/novartis-phase-iii-study-shows-acz885-canakinu mab-reduces-cardiovascular-risk (27 July 2017, date last accessed)
45. Hemani G, Zheng J, Wade KH et al. MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations. bioRxiv 2016;Dec 16:78972
46. Denny JC, Bastarache L, Roden DM. Phenome-wide association studies as a tool to advance precision medicine. Annu Rev Genomics Hum Genet 2016;17:353-73
47. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat Rev Genet 2016;17):129-45
48. Walker AM. Confounding by indication. Epidemiology 1996;7: 335-36
49. Brookhart M, Stürmer T, Glynn R, Rassen J, Schneeweiss S. Confounding control in health care database research: challenges and potential approaches. Med Care 2010;48:S114-20
50. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27: 1133-63
51. Davey Smith G. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr 2011;6:27-43
52. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med 2007;4:e352
53. Groenwold RHH, Hak E, Hoes AW. Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies. J Clin Epidemiol 2009;62:22-28
54. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
55. Petitti D. Commentary: Hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol 2004;33:461-63
56. Lawlor DA, Davey Smith G, Ebrahim S. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health 2004;94:2149-54
57. Yeung SLA, Cheng KK, Zhao J et al. Genetically predicted 17beta-estradiol and cardiovascular risk factors in women: a Mendelian randomization analysis using young women in Hong Kong and older women in the Guangzhou Biobank Cohort Study. Ann Epidemiol 2016;26:171-75
58. Schatzkin A, Abnet CC, Cross AJ et al. Mendelian randomization: how it can-and cannot-help confirm causal relations between nutrition and cancer. Cancer Prev Res (Phila) 2009;2:104-13
59. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22
60. Silverman MG, Ference BA, Im K et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97
61. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80
62. Schmidt AF, Swerdlow DI, Holmes MV et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 2017;5:97-105
63. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 2012;91: 1010-21
64. Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1995. Vital Health Stat 13, 1997;130:1-146
65. Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908773/(26 Jan 2017, date last accessed)
66. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18:401-08
67. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMGCoA reductase inhibitors. Ann Pharmacother 2001;35: 1096-107
68. Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009;67:272-83
69. Joy TR. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858
70. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016;40:304-14
71. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44: 512-25
72. Burgess S, Butterworth AS, Thompson JR. Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors. J Clin Epidemiol 2016;69:208-16
73. Paternoster L, Tilling KM, Davey Smith G. Genetic epidemiology and mendelian randomization for informing disease therapeutics: conceptual and methodological challenges. PLoS Genetics; in press
74. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648-60